Ed Kaye, Stoke Therapeutics CEO
February 18, 2025 10:05 AM EST
Deals

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

Kyle LaHucik

Senior Reporter

A month af­ter Bio­gen sig­naled plans to shift its at­ten­tion to “ex­ter­nal op­por­tu­ni­ties,” it de­liv­ered on that am­bi­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: Atom­wise, a once high-fly­ing AI start­up, taps biotech vet as CEO to lead pared-down com­pa­ny

Pain biotech Lati­go eyes up to $150M raise fol­low­ing Ver­tex's land­mark FDA nod

As part of turn­around, Sol­id Bio re­ports promis­ing ini­tial da­ta for Duchenne gene ther­a­py

Ex­clu­sive: Lux leads $25M Se­ries A in a Lithuan­ian start­up plot­ting US ex­pan­sion

Ar­cus touts ear­ly kid­ney can­cer da­ta as Gilead de­clines op­tion

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times